Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 06, 2025 06:38 ET | Source: Research and Markets

Biosimilars Market Products, Applications and Regulations Overview 2024-2025 & 2030: Patent Expirations Drive Expansion for Cost-Effective Biosimilars, Regulatory Approvals Accelerate Adoption

Dublin, March 06, 2025 (GLOBE NEWSWIRE) -- The "Biosimilars Market - Products, Applications and Regulations" report has been added to ResearchAndMarkets.com's offering. The global biosimilars...
March 06, 2025 05:45 ET | Source: Research and Markets

Liver Cirrhosis Treatment Market Research 2023-2024 & 2024 - Asia Pacific is Predicted to Grow at the Fastest Rate, Owing to the Rising Prevalence of Hepatitis B

Dublin, March 06, 2025 (GLOBE NEWSWIRE) -- The "Liver Cirrhosis Treatment Market Segments by Treatment Type, by End-user, and by Region" report has been added to ResearchAndMarkets.com's...
March 05, 2025 12:36 ET | Source: Research and Markets

Medical Nutrition Global Market Outlook 2025: Medical Nutrition Market Expands at 7% CAGR – Growth in Cancer & Gastrointestinal Applications

Dublin, March 05, 2025 (GLOBE NEWSWIRE) -- The "Medical Nutrition - A Global Market Overview" report has been added to ResearchAndMarkets.com's offering.The global Medical Nutrition market size is...
March 05, 2025 12:00 ET | Source: NATIONAL TSING HUA UNIVERSITY

Researchers at NTHU and NHRI Develop New Drug for Treating Chronic Intestinal Inflammation

NTHU & NHRI develop a new drug to treat chronic intestinal inflammation by blocking PANX1 channels, offering hope for IBD, published in Advanced Science.
February 27, 2025 16:05 ET | Source: Ventyx Biosciences, Inc.

Ventyx Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Corporate Progress

Topline data readouts from multiple Phase 2 studies expected throughout 2025 VTX2735 in patients with recurrent pericarditis in H2VTX3232 in participants with obesity and cardiometabolic risk factors...
February 26, 2025 17:30 ET | Source: Mesoblast Limited

Mesoblast Sets Ryoncil® Price Based on Economic Value of Treatment With Planned Product Availability This Quarter

NEW YORK, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided financial results and...
February 26, 2025 08:19 ET | Source: Biomerica, Inc.

Biomerica Achieves IVDR Certification in the European Union for Food Intolerance Tests Targeting Crohn’s Disease and Ulcerative Colitis

Significant Milestone: Biomerica secures IVDR (In Vitro Diagnostic Regulation) certification, ensuring compliance with stringent European Union standards and allowing sales of the products in the...
February 24, 2025 01:00 ET | Source: Sandoz Group

Sandoz launches biosimilar Pyzchiva® (ustekinumab-ttwe) in the US, offering new treatment for around 12 million patients[1-4]

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules Key biosimilar value driver contributes to Sandoz global growth strategy and moves company closer to becoming #1 in...
February 22, 2025 02:30 ET | Source: Sanofi - Aventis Groupe

Communiqué de presse : ECCO 2025 : de nouvelles données sur le duvakitug illustrent son potentiel de meilleur médicament de sa catégorie pour le traitement de la colite ulcéreuse et de la maladie de Crohn

ECCO 2025 : de nouvelles données sur le duvakitug illustrent son potentiel de meilleur médicament de sa catégorie pour le traitement de la colite ulcéreuse et de la maladie de Crohn De nouvelles...
February 22, 2025 02:20 ET | Source: Teva Pharmaceutical Industries Ltd

Teva and Sanofi Present New Positive Phase 2b Study Results at ECCO 2025 Reinforcing Best-in-Class Potential of Duvakitug (Anti-TL1A) in Ulcerative Colitis and Crohn’s Disease

New detailed data from the RELIEVE UCCD study support overall efficacy and safety of duvakitug in all pre-specified subgroups across the different dosesNew endpoints presented include findings on...